Press release
GM2 Gangliosidosis Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest Regulatory Approvals, Clinical Trials, and Treatment Outlook
GM2 Gangliosidosis Pipeline
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Download the sample pages:
https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
GM2 Gangliosidosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the GM2 Gangliosidosis Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for GM2 Gangliosidosis treatment.
GM2 Gangliosidosis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
GM2 Gangliosidosis Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the GM2 Gangliosidosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
GM2 Gangliosidosis Therapeutics Analysis
There are approx. 8+ key companies which are developing the therapies for GM2 Gangliosidosis. Sanofi has its GM2 Gangliosidosis drug candidates in the most advanced stage, i.e. phase III.
Some of the key companies in the GM2 Gangliosidosis Therapeutics Market include:
• Sanofi
• Sio Gene Therapies
• IntraBio Inc.
• Taysha Gene Therapies
• JCR Pharmaceuticals
• Azafaros B.V.
• Allievex Corp.
• Recursion
• Polaryx
And several others
GM2 Gangliosidosis Therapies covered in the report include:
• Venglustat (Sanofi)
• AXO-AAV-GM2 (Sio Gene Therapies)
And many more
DelveInsight's Report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. GM2 Gangliosidosis Current Treatment Patterns
4. GM2 Gangliosidosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. GM2 Gangliosidosis Late Stage Products (Phase-III)
7. GM2 Gangliosidosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. GM2 Gangliosidosis Discontinued Products
13. GM2 Gangliosidosis Product Profiles
14. GM2 Gangliosidosis Key Companies
15. GM2 Gangliosidosis Key Products
16. Dormant and Discontinued Products
17. GM2 Gangliosidosis Unmet Needs
18. GM2 Gangliosidosis Future Perspectives
19. GM2 Gangliosidosis Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at:
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM2 Gangliosidosis Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest Regulatory Approvals, Clinical Trials, and Treatment Outlook here
News-ID: 2696813 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for GM2
GM2 Gangliosidosis Market is projected to reach USD 332 million by 2034
The global GM2 Gangliosidosis Market-covering Tay-Sachs disease, Sandhoff disease, and related GM2 deficiency disorders-was valued at USD 152 million in 2024 and is projected to reach USD 332 million by 2034, growing at a CAGR of 8.1% during 2025-2034. Market growth is driven by increasing research in gene therapy, better awareness of lysosomal storage disorders (LSDs), advancements in newborn screening, and growth of specialized centers for rare diseases.
Download Full PDF…
GM2 Gangliosidosis Market to Witness Promising Upswing by 2034, DelveInsight For …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast
GM2 gangliosidosis is a group of rare, inherited lysosomal storage disorders caused by mutations in the HEXA, HEXB, or GM2A genes, leading to defective β-hexosaminidase enzyme activity. This results in the accumulation of GM2 ganglioside in neurons, causing progressive neurodegeneration. The most common forms include Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
Although rare, GM2 gangliosidosis represents a critical unmet need…
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
